Journal of Ophthalmology

Anti-VEGF and Beyond


Status
Published

1University Medical Center Goettingen, Goettingen, Germany

2Internationale Innovative Augenchirurgie, Duesseldorf, Germany

3Ruprecht-Karls-University, Munich, Germany

4University of Heidelberg, Heidelberg, Germany


Anti-VEGF and Beyond

Description

Almost one decade ago, the first anti-VEGF drugs to treat neovascular eye disorders were approved by the respective health authorities and brought into routine clinical care. This “revolution” in the field of ophthalmology offered the treating physicians the chance to sustainably save vision for patients affected for the first time. Since these days, the understanding of the efficacy and safety profiles of the anti-VEGF drugs available has constantly grown. However, many open questions remain. Furthermore, new alternative and/or additional substances targeting VEGF and other factors such as PDGF and PIGF are on the horizon to alter and further improve our treatment strategies for neovascular eye diseases.

We invite investigators to contribute manuscripts of original research, clinical studies, and review articles on each aspect of anti-VEGF therapy for neovascular eye diseases. We are particularly interested in articles about new drugs in development or on their way into routine clinical care.

Potential topics include but are not limited to the following:

  • Basic research related to anti-VEGF and new drugs for the treatment of neovascular eye diseases
  • Clinical trials related to anti-VEGF and new drugs for the treatment of neovascular eye diseases
  • Real-world evidence for the treatment of patients affected
  • All aspects of individualized therapy
  • Combining substances with different modes of action
  • Whom, when, and how to switch different anti-VEGF drugs
  • Treatment of retinal ischemia and/or neovascularization with anti-VEGF
  • Treatment of corneal and anterior segment neovascularization

Articles

  • Special Issue
  • - Volume 2017
  • - Article ID 5815021
  • - Editorial

Anti-VEGF and Beyond

T. Bertelmann | H. Kaymak | ... | M. J. Koss
  • Special Issue
  • - Volume 2017
  • - Article ID 6145651
  • - Research Article

The Effect of CM082, an Oral Tyrosine Kinase Inhibitor, on Experimental Choroidal Neovascularization in Rats

Chengda Ren | Hui Shi | ... | Jing Yu
  • Special Issue
  • - Volume 2017
  • - Article ID 9760501
  • - Research Article

The Involvement of β-Catenin/COX-2/VEGF Axis in NMDA-Caused Retinopathy

Dan Ning | Wei Kevin Zhang | ... | He-Bin Tang
  • Special Issue
  • - Volume 2017
  • - Article ID 8984313
  • - Clinical Study

Two-Year Outcome of Aflibercept in Patients with Pigment Epithelial Detachment due to Neovascular Age-Related Macular Degeneration (nAMD) Refractory to Ranibizumab

Thi Ha Chau Tran | Stéphane Dumas | Florence Coscas
  • Special Issue
  • - Volume 2017
  • - Article ID 8035013
  • - Clinical Study

Switching to Aflibercept in Diabetic Macular Edema Not Responding to Ranibizumab and/or Intravitreal Dexamethasone Implant

Antoine Herbaut | Franck Fajnkuchen | ... | Audrey Giocanti-Auregan
  • Special Issue
  • - Volume 2017
  • - Article ID 5831682
  • - Research Article

Switch of Intravitreal Therapy for Macular Edema Secondary to Retinal Vein Occlusion from Anti-VEGF to Dexamethasone Implant and Vice Versa

Amelie Pielen | Anima Desiree Bühler | ... | Bernd Junker
  • Special Issue
  • - Volume 2017
  • - Article ID 4353129
  • - Research Article

Ocular Adverse Effects of Intravitreal Bevacizumab Are Potentiated by Intermittent Hypoxia in a Rat Model of Oxygen-Induced Retinopathy

Jeffrey J. Tan | Charles L. Cai | ... | Kay D. Beharry
  • Special Issue
  • - Volume 2017
  • - Article ID 1645269
  • - Review Article

Use of Anti-VEGF Agents in Glaucoma Surgery

Mark Slabaugh | Sarwat Salim
  • Special Issue
  • - Volume 2017
  • - Article ID 7672485
  • - Clinical Study

Effect of Preoperative Intravitreal Bevacizumab on the Surgical Outcome of Neovascular Glaucoma at Different Stages

Junki Kwon | Kyung Rim Sung
  • Special Issue
  • - Volume 2017
  • - Article ID 7194927
  • - Research Article

Neovascular Age-Related Macular Degeneration in the Very Old (≥90 Years): Epidemiology, Adherence to Treatment, and Comparison of Efficacy

Yousif Subhi | Torben Lykke Sørensen
Journal of Ophthalmology
 Journal metrics
Acceptance rate37%
Submission to final decision93 days
Acceptance to publication34 days
CiteScore1.780
Impact Factor1.580
 Submit